Well, I have chosen not to get into the discussion on critiquing videos.
When I first looked into investing there were quite a few Apricus videos available, and several can still be found. Most were interviews with Damaj. A couple were videos with Apricus scientists explaining DDAIP hand how it worked. They were helpful to me in understanding the company as well as getting to know the players.
At that time (2011-2012) Apricus did not have a polished company website, corporate presentation or, in fact, a statement of corporate goals. For investors, it is my opinion that these are much better and more complete than say a Pascoe video in terms of explaining what Apricus is all about. Institutional investors are not going to base investment decisions on a video for god sakes. If they need visual stuff beyond what is available and beyond what IR can provide them, they can and will fly out to San Diego and meet with Pascoe and get a tour.
As far as Vitaros goes, the question is, "Who is your audience?" The US ED audience does not count as Vitaros is unavailable...not to mention that Apricus does not have the US marketing rights. If the audience is the ED patient in the UK, we all seem to agree that Takeda put up an excellent website on Vitaros. Further, Takeda initiated outreach efforts to UK urologists including the soft launch effort to provide samples to urologists. We don't know all of Takeda's efforts, but Takeda obviously chose not to do a video as that probably would have crossed the no-advertising line. The UK is not a large country. Word will get around. Look at all the media outlets in the UK and EU that picked up the June 16 launch story. However, I am thinking a year for a good initial assessment of market penetration in the UK.
Market Data 
Markets 
AI
